EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Outcomes of Nivolumab‐Plus‐Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J‐ ENCORE Study

Tomokazu Sazuka iD, Katsunori Tatsugami, Suguru Shirotake, Shuzo Hamamoto iD, Masahiro Nozawa, Kazuyuki Numakura, Atsushi Mizokami iD, Tsunenori Kondo, Sei Naito iD, Takashige Abe iD, Kojiro Ohba iD, Go Kimura und 3 weitere

International Journal of Urology · 2026

DOI: 10.1111/iju.70281 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Urology, 2026. Verfasst von Tomokazu Sazuka und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Nivolumab, Kidney Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol-Myers Squibb, Ono Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

J‐ENCORE is a multicenter prospective observational study in Japan involving advanced or metastatic renal cell carcinoma patients receiving nivolumab‐plus‐ipilimumab (NIVO+IPI) as first‐line treatment. The minimum 1‐year observation revealed the efficacy and safety of NIVO+IPI comparable to those in CheckMate 214, and evaluated patient characteristics across subgroups for response and early progression. This minimum 2‐year observation focuses on the post‐treatment status after NIVO+IPI discontinuation.

Methods

The objective response rate (ORR), response duration, progression‐free survival (PFS), overall survival (OS), treatment‐related adverse events (TRAEs), treatment‐free status, and second‐line treatment were evaluated.

Results

The study included 274 patients (median age, 68 years; 24.8% aged ≥ 75 years; 15.7% had an Eastern Cooperative Oncology Group performance status ≥ 2; 58.0%, intermediate risk; 42.0%, poor risk) from 37 sites, with a median follow‐up of 35.4 (range, 24.4–47.0) months. The ORR was 37.6%, with a median real‐world duration of response at 17.1 months; 30.2% had real‐world PFS ≥ 24 months, and the OS rate at 24 months was 67.2%. TRAEs of any grade, grade 3/4, and grade 5 occurred in 77.4%, 42.7%, and 1.1% of patients, respectively. Furthermore, 11.1% experienced late‐onset TRAEs 28–100 days after discontinuation. For patients discontinuing NIVO+IPI due to adverse events, median treatment‐free survival was 7.4 months; 34.9% had a treatment‐free interval ≥ 12 months. Second‐line treatment ORR was 22.0%, with cabozantinib as the most common choice.

Conclusions

We determined the long‐term real‐world effectiveness and safety of NIVO+IPI, providing beneficial information on post‐treatment status. Trial Registration UMIN Clinical Trials Registry number: UMIN000036772; ClinicalTrials.gov identifier: NCT04043975

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellNivolumabKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansAgedMaleFemaleMiddle AgedProspective StudiesAged, 80 and overJapanProgression-Free SurvivalAdultTreatment Outcome

Stichwörter der Autor:innen

Japanipilimumabnivolumabprospective studyrenal cell carcinoma

Substanzen

Nivolumab

Autor:innen und Institutionen

  • Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Department of Urology, Kitakyushu Municipal Medical Center, Fukuoka, Japan.
  • Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
  • Department of Nephro-Urology, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan.
  • Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan.
  • Department of Urology, National Hospital Organization Osaka Minami Medical Center, Osaka, Japan.

ORCID-Profile: Tomokazu Sazuka, Shuzo Hamamoto, Atsushi Mizokami, Sei Naito, Takashige Abe, Kojiro Ohba, Hirotsugu Uemura

Förderung

  • Bristol-Myers Squibb
  • Ono Pharmaceutical

Zitieren

APA

Sazuka, T., Tatsugami, K., Shirotake, S., Hamamoto, S., Nozawa, M., Numakura, K., Mizokami, A., Kondo, T., Naito, S., Abe, T., Ohba, K., Kimura, G., Onodera, S., Yamaguchi, K., & Uemura, H. (2026). Outcomes of Nivolumab‐Plus‐Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J‐ ENCORE Study. International Journal of Urology. https://doi.org/10.1111/iju.70281

Vancouver

Sazuka T, Tatsugami K, Shirotake S, Hamamoto S, Nozawa M, Numakura K, et al. Outcomes of Nivolumab‐Plus‐Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J‐ ENCORE Study. International Journal of Urology. 2026. doi:10.1111/iju.70281

BibTeX
@article{Sazuka2026,
  author = {Sazuka, Tomokazu and Tatsugami, Katsunori and Shirotake, Suguru and Hamamoto, Shuzo and Nozawa, Masahiro and Numakura, Kazuyuki and Mizokami, Atsushi and Kondo, Tsunenori and Naito, Sei and Abe, Takashige and Ohba, Kojiro and Kimura, Go and Onodera, Shunta and Yamaguchi, Katsumi and Uemura, Hirotsugu},
  title = {Outcomes of Nivolumab‐Plus‐Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J‐ ENCORE Study},
  journal = {International Journal of Urology},
  year = {2026},
  doi = {10.1111/iju.70281}
}
Kostenlos starten →